Report of Foreign Issuer (6-k)
January 29 2013 - 9:14AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF
1934
For the month of January 2013
Commission File Number: 001-34564
China Nuokang
Bio-Pharmaceutical Inc.
No. 18-1 East Nanping Road
Hunnan National New & High-tech Development Zone
Shenyang,
Liaoning Province
Peoples Republic of China 110171
(Address of principal executive offices)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F
x
Form 40-F
¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
¨
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
China Nuokang Bio-Pharmaceutical Inc.
|
|
|
By:
|
|
/s/ Baizhong Xue
|
Name:
|
|
Baizhong Xue
|
Title:
|
|
Chairman and Chief Executive Officer
|
Date: January 29, 2013
Exhibit Index
|
|
|
Exhibit No.
|
|
Description
|
|
|
Exhibit 99.1
|
|
Press Release dated January 29, 2013
|
Exhibit 99.1
China Nuokang Bio-Pharmaceutical Inc. to Reconvene Adjourned
Extraordinary General
Meeting of Shareholders
BEIJING, January 29, 2013 (GLOBE NEWSWIRE) China Nuokang Bio-Pharmaceutical Inc. (Nasdaq Global Market:
NKBP) (Nuokang or the Company) announced today that it will reconvene the extraordinary general meeting of shareholders (the EGM) that was previously adjourned on January 15, 2013. The EGM will be reconvened
at 9:30 a.m. (Beijing time) on February 6, 2013, at 26th Floor, Gloucester Tower, The Landmark, 15 Queens Road Central, Hong Kong, to consider and vote on, among other things, the proposal to authorize and approve the previously announced
agreement and plan of merger (the Merger Agreement) dated September 27, 2012, among the Company, Kingbird Investment Inc. (Parent) and Kingbird Mergerco. Inc. (Merger Sub), and, solely for the purposes of
Section 6.16 thereof, Anglo China Bio-technology Investment Holdings Limited and Britain Ukan Technology Investment Holdings (Group) Limited, and the plan of merger required to be filed with the Registrar of Companies of the Cayman Islands,
substantially in the form attached as Exhibit A to the Merger Agreement (the Plan of Merger) and the transactions contemplated thereby (including the proposed merger).
About China Nuokang Bio-Pharmaceutical Inc.
China Nuokang Bio-Pharmaceutical Inc. (Nasdaq: NKBP)
is a leading biopharmaceutical company in China focused on the research, development, manufacture, marketing and sales of hospital-based medical products. The Company provides a diversified portfolio of products across more than 4,200 hospitals in
China Nuokangs principal products include Baquting®, Chinas leading hemocoagulase product by market share, Kaitong®, a lipid emulsion alprostadil product for the treatment of peripheral vascular diseases, cardiocerebral
microcirculation disorders and post-surgery thrombosis; and alpha lipoic acid capsules, or ALA, an antioxidant product that addresses diabetic neuropathy. The Companys product pipeline includes product candidates under development in
hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. Please visit www.nkbp.com for more information.
Forward-Looking Statements
This press release
contains forward-looking statements relating to the potential acquisition of the Company by an affiliate of Mr. Baizhong Xue, the Chairman and Chief Executive Officer of the Company. These are forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. The actual results of the
transaction could vary materially as a result of a number of factors, including: uncertainties as to how the Companys shareholders will vote at the extraordinary general meeting; the possibility that competing offers will be made; and the
possibility that various closing conditions for the transaction may not be satisfied or waived. These forward-looking statements reflect the Companys expectations as of the date of this press release. The Company does not undertake any
obligation to update any forward-looking statement, except as required under applicable law.
CONTACT:
China Nuokang Bio-Pharmaceutical Inc.
Mr. Steven Duan
Vice President of Investor Relations
Email:
dsz@nkbp.com
ICR, Inc.
Mr. Rob Koepp
Tel: (+86) 10-6583-7516
or (646) 405-5180
Email: robert.koepp@icrinc.com
2
China Nuokang Bio-Pharmaceutical Inc. ADS, Each Representing Eight Ordinary Shares (MM) (NASDAQ:NKBP)
Historical Stock Chart
From Apr 2024 to May 2024
China Nuokang Bio-Pharmaceutical Inc. ADS, Each Representing Eight Ordinary Shares (MM) (NASDAQ:NKBP)
Historical Stock Chart
From May 2023 to May 2024